Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Operating Margin: 2019-2025

Historic Operating Margin for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -120.30%.

  • BridgeBio Pharma's Operating Margin rose 689837.00% to -120.30% in Q3 2025 from the same period last year, while for Sep 2025 it was -172.39%, marking a year-over-year increase of 7759.00%. This contributed to the annual value of -267.22% for FY2024, which is 626153.00% up from last year.
  • BridgeBio Pharma's Operating Margin amounted to -120.30% in Q3 2025, which was up 0.95% from -121.45% recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Operating Margin peaked at 19,953.49% during Q4 2021, and registered a low of -38,200.00% during Q3 2022.
  • Over the past 3 years, BridgeBio Pharma's median Operating Margin value was -3,854.61% (recorded in 2023), while the average stood at -4,465.75%.
  • Over the last 5 years, BridgeBio Pharma's Operating Margin had its largest YoY gain of 12,445,267bps in 2021, and its largest YoY loss of 3,881,206bps in 2021.
  • Over the past 5 years, BridgeBio Pharma's Operating Margin (Quarterly) stood at 19,953.49% in 2021, then crashed by 2,686,430bps to -6,910.80% in 2022, then plummeted by 325,630bps to -10,167.11% in 2023, then soared by 632,442bps to -3,842.69% in 2024, then surged by 689,837bps to -120.30% in 2025.
  • Its last three reported values are -120.30% in Q3 2025, -121.45% for Q2 2025, and -89.49% during Q1 2025.